The American Heart Association (AHA) will host its 2025 Scientific Sessions from November 7 to November 10 in New Orleans, Louisiana. As the premier global event for cardiovascular health and science, the four-day event offers attendees the opportunity to establish career-changing connections, discover the latest scientific breakthroughs, and hear from world leaders in cardiovascular health.
Registration for the AHA 2025 Scientific Sessions is now open to AHA members and non-members. Virtual options are also available at reduced costs and grant access to pre-selected events, which will be livestreamed. Additionally, physicians, physician assistants, nurse practitioners, nurses, and pharmacists can claim up to 24.75 CE credits for participating.
The AHA points out some exciting new additions to this year’s Scientific Sessions, including expanded moderated digital poster presentations (some of which we preview below), an enhanced Simulation Zone offering immersive hands-on experiences, new guideline sessions, and more.
Today, we're taking a look ahead at some of the exciting educational sessions on hypertrophic cardiomyopathy. The selection of sessions below represents just some of the many sessions that attendees can experience at the AHA 2025 Scientific Sessions. The dates and times are accurate as of October 7, 2025. For the most up-to-date look at the event's schedule, visit the official AHA Scientific Sessions planner.
Preview of Hypertrophic Cardiomyopathy Sessions
- Cardiovascular Seminar
- November 7, 8:00 AM – 9:15 AM
- Description: During this session, attendees will identify phenocopies of hypertrophic cardiomyopathy through imaging techniques, integrate artificial intelligence into clinical workflows, predict risk of sudden death utilizing imaging modalities, and interpret echocardiograms for managing patients on cardiac myosin inhibitors.
- Cardiovascular Seminar
- November 7, 12:45 PM – 2:30 PM
- Description: This session will examine the role of exercise testing to determine treatment strategy and response, summarize the latest research on cardiac myosin inhibitor therapy for obstructive and nonobstructive hypertrophic cardiomyopathy, describe novel techniques for septal reduction therapy, and synthesize an approach to team-based hypertrophic cardiomyopathy care.
Hypertrophic Cardiomyopathy Medical Society Oral Abstracts
- Abstract Oral Session
- November 7, 2:30 PM – 3:45 PM
- Description: The top-rated abstract submissions will be presented orally in a moderated format. The following abstracts will be presented accompanied by brief question-and-answer periods:
- Characteristics and Long-Term Outcomes of Asymptomatic Patients with Hypertrophic Cardiomyopathy Undergoing Treadmill Stress Echocardiography
- Long-term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM
- Dual SGLT1 and 2 Inhibition with Sotagliflozin Ameliorates Adverse Cardiac Remodeling and Diastolic Dysfunction in Mice with Hypertrophic Cardiomyopathy Due to Tropomyosin E180G Mutation
- Artificial Intelligence Versus Clinician Maximum Wall Thickness Measurement on Cardiac MRI for Mortality Prediction
- Body Mass Index, Diastolic Blood Pressure, and Hypertrophic Cardiomyopathy Polygenic Background Differentially Modify Hypertrophic Cardiomyopathy Risk
Hypertrophic Cardiomyopathy Medical Society Posters
- Poster Presentation
- November 7, 6:30 PM – 7:30 PM
- Description: The latest topics in hypertrophic cardiomyopathy will be presented in poster format. The following are a preview of some of the presentations scheduled for this poster session:
- Artificial Intelligence-Enabled Electrocardiogram for the Detection of Elevated Filling Pressure in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis
- Five-Year Outcomes of Glucagon-Like Peptide-1 Agonists in Obstructive Hypertrophic Cardiomyopathy: A Population-Based Retrospective Study
- Longterm Outcomes of Percutaneous endocardial Septal Radiofrequency Ablation for Patients with Hypertrophic Obstructive Cardiomyopathy
- Real-World Sudden Cardiac Death Risk Prediction in Hypertrophic Cardiomyopathy Using State-of-the-Art Thinking Models
- Main Event
- November 8, 9:45 AM – 11:00 AM
- Description: This session will be the inaugural collaborative session between the AHA and HCM Society. It will feature cross disciplinary faculty from basic science, genetics, heart failure, imaging and surgery, highlighting the latest updates in new therapies for hypertrophic cardiomyopathy. The following presentations are set to take place during this session:
- More than Pretty Pictures: Deep Phenotyping for SCD Risk Stratification and Therapeutic Monitoring
- Surgical innovations in Hypertrophic Cardiomyopathy: More Than Just A Shave?
- Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy - Altering The Natural History or Am I Delusional?
- Gene Therapy: The Next Frontier or Fool's Gold?
- TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy
Targeting the Thickened Heart: Advanced in Hypertrophic Cardiomyopathy Therapy
- Moderated Digital Poster Session
- November 8, 10:45 AM – 12:00 PM
- Description: This poster session highlights emerging therapeutic strategies in hypertrophic cardiomyopathy, from myosin inhibitors and metabolic modulators to septal reduction techniques and gene-targeted approaches. Presenters will share clinical and translational data that illuminate the evolving landscape of hypertrophic cardiomyopathy management, with a focus on symptom relief, disease modification, and improved patient outcomes. Presentations will be followed by brief question-and-answer periods. Some of the presentations include:
- Long-Term Outcomes of Outcomes of Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy: Is an Earlier Intervention Better?
- Mavacamten: Real-World Experience from 34 Months of Risk Evaluation and Mitigation Strategy (REMS) Program
- Outcomes Associated with GLP1 Receptor Agonist Use in Hypertrophic Cardiomyopathy
- Hypertrophic Cardiomyopathy in a Patient with BAG3–Associated Charcot-Marie-Tooth Disease: A Rare Cardiac Manifestation
Innovation & Precision Medicine in Hypertrophic Cardiomyopathy
- Moderated Digital Poster Session
- November 10, 10:45 AM – 11:35 AM
- Description: This session will focus on advancements in the diagnosis, treatment, and risk stratification of hypertrophic cardiomyopathy, particularly the obstructive form. A major theme is the real-world effectiveness and safety of mavacamten, a cardiac myosin inhibitor, both alone and in combination with standard therapies. Studies also explore genetic underpinnings of hypertrophic cardiomyopathy (e.g., novel β-MYH7 mutations), the use of AI for diagnosis and risk prediction, and gender disparities in outcomes after septal ablation. Presentations will be followed by brief question-and-answer periods. Some of the presentations include:
- Efficacy of Mavacamten Combined with Standard Therapy in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study
- Real-World Outcomes of Mavacamten Monotherapy in Obstructive Hypertrophic Cardiomyopathy: Symptomatic and Hemodynamic Improvements Without Increased Adverse Events
- AI-Driven Electrocardiographic Risk Stratification for Ventricular Arrhythmias in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis
Sign up for alerts and stay informed on more upcoming conference previews and conference recaps.
Copyright © 2025 Guideline Central, all rights reserved.